Vigil Neuroscience is a microglia-focused therapeutics company
Our purpose is clear: to treat rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease.
OUR APPROACH
Leveraging recent research implicating microglial dysfunction in neurodegenerative diseases, we are utilizing a precision medicine approach to develop a pipeline of therapeutic candidates, initially addressing genetically defined patient subpopulations, that we believe will activate and restore microglial function.
Our precision medicine approach begins with rare, genetically defined diseases for which microglial dysfunction is believed to be a key driver of disease pathology and then utilizes findings from these efforts to inform expansion into larger and more common neurodegenerative diseases. We believe this iterative, sequential approach is a key differentiator, potentially allowing us to generate clinical proof of concept efficiently and leverage our initial development programs as well as research by others, in pursuing additional neurodegenerative disease opportunities.
Our strategy is driven by our mission to bring novel therapies to patients in disease areas of high unmet need as quickly as possible.
OUR PROGRAMS
Our first therapeutic candidates are designed to activate human triggering receptor expressed on myeloid cells 2 (TREM2), a key microglial receptor protein that mediates responses to environmental signals in order to maintain brain health, and whose dysfunction is linked to neurodegeneration.
PATIENTS
Engaging with and understanding patients and their experiences is central to our approach. We collaborate with patients, caregivers, and patient advocacy groups to best serve the patient community.
